Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4235489 | 0.77 | GRIN2B (0.52) | MTNR1AMTNR1BCYP1A2CYP2C9CA1 | |
| SCHEMBL7926562 | 0.76 | MTNR1A (0.64) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| Hydrochloric Acid SCHEMBL7926558 | 0.75 | MTNR1A (0.63) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL4217159 | 0.74 | MTNR1A (0.73) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL4226587 | 0.74 | MTNR1A (0.50) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| Hydrochloric Acid SCHEMBL7935435 | 0.72 | MTNR1A (0.62) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL8074280 | 0.72 | DRD2 (0.83) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL8074250 | 0.72 | DRD2 (0.83) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL7543711 | 0.72 | DRD2 (0.83) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL9241035 | 0.72 | MTNR1A (0.60) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096104-A1 | Organic diamines as mGluR7 modulators | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080242698-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242698-A1 | Organic Compounds | AOC1, OTC, ODC1 | MTNR1A 2710/4885MTNR1B 2160/4885CYP1A2 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.